Egetis Therapeutics
egetis.com
Actively hiring
Rare Disease Therapeutics
Prescription Drugs
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Flerie
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2018
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Flerie Similar startupsby what they do, their industry and backers
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high…
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development…
DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology…
Mendra is a venture-backed rare-disease biopharma accelerating the development and commercialization of de-risked breakthrough therapies.
Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading…
Overview
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.
News
Report
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (
Read more
Report
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (
Read more
Report
Report
Pro access
Upgrade to see all 17 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.